5-S-Cysteinyldopa (BioDeep_00000898977)

   


代谢物信息卡片


5-S-Cysteinyldopa

化学式: C12H16N2O6S (316.0729036)
中文名称:
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: C1=C(C=C(C(=C1O)O)SCC(C(=O)[O-])[NH3+])CC(C(=O)[O-])[NH3+]
InChI: InChI=1S/C12H16N2O6S/c13-6(11(17)18)1-5-2-8(15)10(16)9(3-5)21-4-7(14)12(19)20/h2-3,6-7,15-16H,1,4,13-14H2,(H,17,18)(H,19,20)/t6-,7-/m0/s1

描述信息

同义名列表

1 个代谢物同义名

5-S-Cysteinyldopa



数据库引用编号

3 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:

  • PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。



文献列表

  • Wenjiao Shi, Jian Lou, Xiaodan Zhang, Yun Ji, Xiaojian Weng, Jianer Du. Adipose tissue alleviates the stress response by releasing adiponectin during laparoscopic surgery in patients with colorectal cancer. Lipids in health and disease. 2021 Nov; 20(1):166. doi: 10.1186/s12944-021-01595-6. [PMID: 34801038]
  • Kazumasa Wakamatsu, Satoshi Fukushima, Akane Minagawa, Toshikazu Omodaka, Tokimasa Hida, Naohito Hatta, Minoru Takata, Hisashi Uhara, Ryuhei Okuyama, Hironobu Ihn. Significance of 5-S-Cysteinyldopa as a Marker for Melanoma. International journal of molecular sciences. 2020 Jan; 21(2):. doi: 10.3390/ijms21020432. [PMID: 31936623]
  • Toshikazu Omodaka, Akane Minagawa, Hisashi Uhara, Kazumasa Wakamatsu, Tomonobu Koizumi, Yoshiharu Yokokawa, Hiroshi Koga, Ryuhei Okuyama. Serum 5-S-cysteinyldopa behavior in the early phase of nivolumab treatment of 12 melanoma patients. The Journal of dermatology. 2018 Nov; 45(11):1340-1344. doi: 10.1111/1346-8138.14605. [PMID: 30144152]
  • Hiroshi Umemura, Osamu Yamasaki, Tatsuya Kaji, Masaki Otsuka, Kenji Asagoe, Minoru Takata, Keiji Iwatsuki. Usefulness of serum 5-S-cysteinyl-dopa as a biomarker for predicting prognosis and detecting relapse in patients with advanced stage malignant melanoma. The Journal of dermatology. 2017 Apr; 44(4):449-454. doi: 10.1111/1346-8138.13651. [PMID: 27786364]
  • Tokimasa Hida, Akihiro Yoneta, Kazumasa Wakamatsu, Kenji Yanagisawa, Yasue Ishii-Osai, Yuji Kan, Junji Kato, Toshiharu Yamashita. Circulating melanoma cells as a potential biomarker to detect metastasis and evaluate prognosis. The Australasian journal of dermatology. 2016 May; 57(2):145-9. doi: 10.1111/ajd.12455. [PMID: 26931184]
  • Hironori Mizutani, Satoshi Fukushima, Shinichi Masuguchi, Junji Yamashita, Azusa Miyashita, Satoshi Nakahara, Jun Aoi, Yuji Inoue, Masatoshi Jinnin, Hironobu Ihn. Serum levels of leptin receptor in patients with malignant melanoma as a new tumor marker. Experimental dermatology. 2013 Nov; 22(11):748-9. doi: 10.1111/exd.12238. [PMID: 24433182]
  • Koichi Takeda, Tsuneaki Kenzaka, Shigehiro Kuroki, Eiji Kajii. Melanuria in the diagnosis of metastatic melanoma. Internal medicine (Tokyo, Japan). 2012; 51(12):1649. doi: 10.2169/internalmedicine.51.7586. [PMID: 22728512]
  • Gaëlle Martin, François Mansion, Virginie Houbart, Philippe Paquet, Andrée Rorive, Patrice Chiap, Jacques Crommen, Anne-Catherine Servais, Marianne Fillet. Pre-study and in-study validation of a SPE-LC-MS-MS method for the determination of 5-S-cysteinyldopa, a melanoma biomarker, in human plasma. Talanta. 2011 Apr; 84(2):280-6. doi: 10.1016/j.talanta.2010.12.047. [PMID: 21376945]
  • Lucia Panzella, Kazumasa Wakamatsu, Giuseppe Monfrecola, Shosuke Ito, Fabio Ayala, Alessandra Napolitano. Increased cysteinyldopa plasma levels hint to melanocyte as stress sensor in psoriasis. Experimental dermatology. 2011 Mar; 20(3):288-90. doi: 10.1111/j.1600-0625.2010.01211.x. [PMID: 21323749]
  • Kazutaka Murakami, Yukiko Nakanishi, Kazumasa Wakamatsu, Koichiro Yamamoto, Nahoko Kohriyama, Midori Hasegawa, Makoto Tomita, Kunihiro Nabeshima, Yoshiyuki Hiki, Shinsuke Asano, Shiro Kawashima, Yasuhiro Ito, Yoshiro Fujita, Hiroaki Asada, Shigeru Nakai, Satoshi Sugiyama, Shosuke Ito. Serum levels of 5-s-cysteinyldopa are correlated with skin colors in hemodialysis patients but not in peritoneal dialysis patients. Blood purification. 2009; 28(3):209-15. doi: 10.1159/000230812. [PMID: 19648740]
  • K Kikuchi, K Wakamatsu, Y Tada, M Komine, S Ito, K Tamaki. Serum 5-S-cysteinyldopa levels in patients with psoriasis undergoing narrowband ultraviolet B phototherapy. Clinical and experimental dermatology. 2008 Nov; 33(6):750-3. doi: 10.1111/j.1365-2230.2008.02792.x. [PMID: 18954414]
  • Gaëlle B Martin, Patrice Chiap, Philippe Paquet, Gerald Pierard, Pascal de Tullio, Yves Martin, Eric Rozet, Philippe Hubert, Jacques Crommen, Marianne Fillet. Development of a mass spectrometry method for the determination of a melanoma biomarker, 5-S-cysteinyldopa, in human plasma using solid phase extraction for sample clean-up. Journal of chromatography. A. 2007 Jul; 1156(1-2):141-8. doi: 10.1016/j.chroma.2006.12.088. [PMID: 17229429]
  • Kazutaka Murakami, Kazumasa Wakamatsu, Yukiko Nakanishi, Hiroki Takahashi, Satoshi Sugiyama, Shosuke Ito. Serum levels of pigmentation markers are elevated in patients undergoing hemodialysis. Blood purification. 2007; 25(5-6):483-9. doi: 10.1159/000112516. [PMID: 18089933]
  • Kazumasa Wakamatsu, Shosuke Ito. Evaluation of melanin-related metabolites as markers of solar ultraviolet-B radiation. Pigment cell research. 2006 Oct; 19(5):460-4. doi: 10.1111/j.1600-0749.2006.00324.x. [PMID: 16965276]
  • Yoshiaki Ikuta, Tetsuya Nakatsura, Toshiro Kageshita, Satoshi Fukushima, Shosuke Ito, Kazumasa Wakamatsu, Hideo Baba, Yasuharu Nishimura. Highly sensitive detection of melanoma at an early stage based on the increased serum secreted protein acidic and rich in cysteine and glypican-3 levels. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 Nov; 11(22):8079-88. doi: 10.1158/1078-0432.ccr-05-1074. [PMID: 16299239]
  • Tomohisa Hirobe, Sakae Takeuchi, Eri Hotta, Kazumasa Wakamatsu, Shosuke Ito. Pheomelanin production in the epidermis from newborn agouti mice is induced by the expression of the agouti gene in the dermis. Pigment cell research. 2004 Oct; 17(5):506-14. doi: 10.1111/j.1600-0749.2004.00176.x. [PMID: 15357837]
  • Y Asada, S Arakawa, S Fujiwara, F Sato, K Kaneda. High serum level of 5-S-cysteinyldopa in chronic renal failure does not always indicate melanoma progression. The British journal of dermatology. 2004 Aug; 151(2):515-6. doi: 10.1111/j.1365-2133.2004.06096.x. [PMID: 15327571]
  • K Arstrand, A Kullman, R Andersson, T Rasmuson, B Kågedal. Improved method for analysis of cysteinyldopa in human serum. Scandinavian journal of clinical and laboratory investigation. 2004; 64(6):559-64. doi: 10.1080/00365510410007026. [PMID: 15370461]
  • Tomohisa Hirobe, Kazumasa Wakamatsu, Shosuke Ito. Changes in the proliferation and differentiation of neonatal mouse pink-eyed dilution melanocytes in the presence of excess tyrosine. Pigment cell research. 2003 Dec; 16(6):619-28. doi: 10.1046/j.1600-0749.2003.00091.x. [PMID: 14629719]
  • Akihiko Takasaki, Dzeneta Nezirević, Kerstin Arstrand, Kazumasa Wakamatsu, Shosuke Ito, Bertil Kågedal. HPLC analysis of pheomelanin degradation products in human urine. Pigment cell research. 2003 Oct; 16(5):480-6. doi: 10.1034/j.1600-0749.2003.00086.x. [PMID: 12950724]
  • Kazumasa Wakamatsu, Mika Yokochi, Akiko Naito, Toshiro Kageshita, Shosuke Ito. Comparison of phaeomelanin and its precursor 5-S-cysteinyldopa in the serum of melanoma patients. Melanoma research. 2003 Aug; 13(4):357-63. doi: 10.1097/00008390-200308000-00004. [PMID: 12883361]
  • Swaran J S Flora, Manisha Pande, Ashish Mehta. Beneficial effect of combined administration of some naturally occurring antioxidants (vitamins) and thiol chelators in the treatment of chronic lead intoxication. Chemico-biological interactions. 2003 Jun; 145(3):267-80. doi: 10.1016/s0009-2797(03)00025-5. [PMID: 12732454]
  • T Bánfalvi, K Gilde, M Gergye, M Boldizsár, T Kremmer, S Ottó. Use of serum 5-S-CD and S-100B protein levels to monitor the clinical course of malignant melanoma. European journal of cancer (Oxford, England : 1990). 2003 Jan; 39(2):164-9. doi: 10.1016/s0959-8049(02)00487-2. [PMID: 12509947]
  • T Meyer, A Hauschild, A Kromminga, J Hartleb, R Arndt, E Christophers, E Stockfleth. Clinical evaluation of 5-S-cysteinyldopa testing using a new and optimized detection system as a tumour marker for malignant melanoma. Melanoma research. 2002 Oct; 12(5):471-7. doi: 10.1097/00008390-200209000-00009. [PMID: 12394189]
  • Y Matsushita, N Hatta, K Wakamatsu, K Takehara, S Ito, M Takata. Melanoma inhibitory activity (MIA) as a serum marker for early detection of post-surgical relapse in melanoma patients: comparison with 5-S-cysteinyldopa. Melanoma research. 2002 Aug; 12(4):319-23. doi: 10.1097/00008390-200208000-00003. [PMID: 12170180]
  • K Wakamatsu, T Kageshita, M Furue, N Hatta, Y Kiyohara, J Nakayama, T Ono, T Saida, M Takata, T Tsuchida, H Uhara, A Yamamoto, N Yamazaki, A Naito, S Ito. Evaluation of 5-S-cysteinyldopa as a marker of melanoma progression: 10 years' experience. Melanoma research. 2002 Jun; 12(3):245-53. doi: 10.1097/00008390-200206000-00008. [PMID: 12140381]
  • Teodóra Bánfalvi, Mariann Boldizsár, Maria Gergye, Katalin Gilde, Tibor Kremmer, Szabolcs Ottó. Comparison of prognostic significance of serum 5-S-Cysteinyldopa, LDH and S-100B protein in Stage III-IV malignant melanoma. Pathology oncology research : POR. 2002; 8(3):183-7. doi: 10.1007/bf03032392. [PMID: 12515998]
  • T Bánfalvi, K Gilde, M Boldizsár, T Kremmer. Clinical significance of 5-S-cysteinyldopa monitoring in patients with malignant melanoma. Neoplasma. 2002; 49(2):121-5. doi: NULL. [PMID: 12088105]
  • T Kageshita, Y Funasaka, M Ichihashi, K Wakamatsu, S Ito, T Ono. Tissue factor expression and serum level in patients with melanoma does not correlate with disease progression. Pigment cell research. 2001 Jun; 14(3):195-200. doi: 10.1034/j.1600-0749.2001.140309.x. [PMID: 11434567]
  • J L Magnay, J Tong, R Drangova, A D Baines. Production of cysteinyl-dopamine during intravenous dopamine therapy. Kidney international. 2001 May; 59(5):1891-8. doi: 10.1046/j.1523-1755.2001.0590051891.x. [PMID: 11318961]
  • T Bánfalvi, K Gilde, M Boldizsár, Z Fejös, B Horváth, G Liszkay, E Beczássy, T Kremmer. Serum concentration of 5-S-cysteinyldopa in patients with melanoma. European journal of clinical investigation. 2000 Oct; 30(10):900-4. doi: 10.1046/j.1365-2362.2000.00710.x. [PMID: 11029605]
  • R Kärnell, B Kågedal, C Lindholm, B Nilsson, K Arstrand, U Ringborg. The value of cysteinyldopa in the follow-up of disseminated malignant melanoma. Melanoma research. 2000 Aug; 10(4):363-9. doi: 10.1097/00008390-200008000-00008. [PMID: 10985671]
  • P Manini, M d'Ischia, G Prota. A novel octahydropyridobenzothiazepine metabolite in human urine: biomimetic formation from the melanogen 5-S-cysteinyldopa and formaldehyde via a peculiar sulfur-controlled double Pictet-Spengler condensation. The Journal of organic chemistry. 2000 Jul; 65(14):4269-73. doi: 10.1021/jo991969c. [PMID: 10891125]
  • M Johansson, E K Pisa, V Törmänen, K Arstrand, B Kågedal. Quantitative analysis of tyrosinase transcripts in blood. Clinical chemistry. 2000 Jul; 46(7):921-7. doi: 10.1093/clinchem/46.7.921. [PMID: 10894834]
  • J Hartleb, Y Damm, R Arndt, E Christophers, E Stockfleth. Determination of 5-S-cysteinyldopa in plasma and urine using a fully automated solid-phase extraction--high-performance liquid chromatographic method for an improvement of specificity and sensitivity of this prognostic marker of malignant melanoma. Journal of chromatography. B, Biomedical sciences and applications. 1999 Apr; 727(1-2):31-42. doi: 10.1016/s0378-4347(99)00098-5. [PMID: 10360420]
  • T Bánfalvi, K Gilde, M Boldizsár, T Kremmer, S Ottó. Serum levels of S-100 protein and 5-S-cysteinyldopa as markers of melanoma progression. Pathology oncology research : POR. 1999; 5(3):218-22. doi: 10.1053/paor.1999.0218. [PMID: 10491021]
  • Y Suenaga, H Katabuchi, H Okamura, T Kageshita, T Ono. Increased serum levels of 5-S-cysteinyldopa and intercellular adhesion molecule-1 in a patient with a uterine amelanotic metastasis from a primary vaginal malignant melanoma. Gynecologic oncology. 1999 Jan; 72(1):107-10. doi: 10.1006/gyno.1998.5176. [PMID: 9889040]
  • H Goto, T Tenou, H Kudo, T Iwasaki, R Muramatsu, M Usui, K Wakamatsu, S Ito. [5-S-cysteinyldopa as a tumor marker for primary uveal malignant melanoma]. Nippon Ganka Gakkai zasshi. 1998 May; 102(5):319-26. doi: NULL. [PMID: 9619024]
  • S Meyerhöffer, Z Lindberg, A Häger, B Kågedal, I Rosdahl. Urinary excretion of 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid in children. Acta dermato-venereologica. 1998 Jan; 78(1):31-5. doi: 10.1080/00015559850135797. [PMID: 9498023]
  • I Wimmer, J C Meyer, B Seifert, R Dummer, A Flace, G Burg. Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy. Cancer research. 1997 Nov; 57(22):5073-6. doi: NULL. [PMID: 9371505]
  • R Kärnell, E von Schoultz, L O Hansson, B Nilsson, K Arstrand, B Kågedal. S100B protein, 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid as biochemical markers for survival prognosis in patients with malignant melanoma. Melanoma research. 1997 Oct; 7(5):393-9. doi: 10.1097/00008390-199710000-00005. [PMID: 9429222]
  • Y Sasaki, H Shimizu, W Naka, E Takeshita, T Nishikawa. Evaluation of the clinical usefulness of measuring urinary excretion of 5-S-cysteinyldopa in melanoma: ten years' experience of 50 patients. Acta dermato-venereologica. 1997 Sep; 77(5):379-81. doi: 10.2340/0001555577379381. [PMID: 9298132]
  • M Benathan, F Labidi. Insulin inhibits tyrosinase activity and 5-S-cysteinyldopa formation in human melanoma cells. Acta dermato-venereologica. 1997 Jul; 77(4):281-4. doi: 10.2340/0001555577281284. [PMID: 9228219]
  • M Hasegawa, M Takata, N Hatta, K Wakamatsu, S Ito, K Takehara. Simultaneous measurement of serum 5-S-cysteinyldopa, circulating intercellular adhesion molecule-1 and soluble interleukin-2 receptor levels in Japanese patients with malignant melanoma. Melanoma research. 1997 Jun; 7(3):243-51. doi: 10.1097/00008390-199706000-00009. [PMID: 9195564]
  • S Memoli, A Napolitano, M d'Ischia, G Misuraca, A Palumbo, G Prota. Diffusible melanin-related metabolites are potent inhibitors of lipid peroxidation. Biochimica et biophysica acta. 1997 May; 1346(1):61-8. doi: 10.1016/s0005-2760(97)00018-0. [PMID: 9187303]
  • S Hirai, T Kageshita, T Kimura, M Tsujisaki, K Imai, K Wakamatsu, S Ito, T Ono. Serum levels of sICAM-1 and 5-S-cysteinyldopa as markers of melanoma progression. Melanoma research. 1997 Feb; 7(1):58-62. doi: 10.1097/00008390-199702000-00009. [PMID: 9067966]
  • K Shimpo, T Chihara, M Hibiya, S Ito, T Nagatsu. [Amines and pteridines]. Nihon rinsho. Japanese journal of clinical medicine. 1996 Jun; 54(6):1515-20. doi: . [PMID: 8691603]
  • J E Ahlskog, R J Uitti, P A Low, G M Tyce, J F O'Brien, K K Nickander. Levodopa and deprenyl treatment effects on peripheral indices of oxidant stress in Parkinson's disease. Neurology. 1996 Mar; 46(3):796-801. doi: 10.1212/wnl.46.3.796. [PMID: 8618686]
  • J Nakayama, M Takeuchi, H Mayumi, S Nagae, K Matsuda, H Yasui, S Takahashi, Y Hori. Two cases of metastatic malignant melanoma of the lower limb treated with hyperthermic isolated limb perfusion and concomitant infusion of either carboplatin or beta-interferon. The Journal of dermatology. 1996 Jan; 23(1):6-15. doi: . [PMID: 8720252]
  • Y Hanawa, K Wakamatsu, S Ikeda. Serum concentration of 5-S-cysteinyldopa in pediatric patients with giant pigmented nevi. The Journal of dermatology. 1996 Jan; 23(1):16-21. doi: 10.1111/j.1346-8138.1996.tb03962.x. [PMID: 8720253]
  • S Schmitz, P D Thomas, T M Allen, M J Poznansky, K Jimbow. Dual role of melanins and melanin precursors as photoprotective and phototoxic agents: inhibition of ultraviolet radiation-induced lipid peroxidation. Photochemistry and photobiology. 1995 Jun; 61(6):650-5. doi: 10.1111/j.1751-1097.1995.tb09883.x. [PMID: 7568412]
  • K Wakamatsu, S Ito. Seasonal variation in serum concentration of 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid in healthy Japanese. Pigment cell research. 1995 Jun; 8(3):132-4. doi: 10.1111/j.1600-0749.1995.tb00653.x. [PMID: 7567788]
  • Z Ye, T Kageshita, T Ishihara, S Ito, T Ono. A case of malignant melanoma: disease progression correlated with serum levels of 5-S-Cysteinyldopa (5-S-CD) and intercellular adhesion molecule-1 (ICAM-1). The Journal of dermatology. 1995 May; 22(5):370-5. doi: NULL. [PMID: 7673560]
  • K Wakamatsu, S Ito. Improved HPLC determination of 5-S-cysteinyldopa in serum. Clinical chemistry. 1994 Mar; 40(3):495-6. doi: 10.1093/clinchem/40.3.495. [PMID: 8131290]
  • T Horikoshi, S Ito, K Wakamatsu, H Onodera, H Eguchi. Evaluation of melanin-related metabolites as markers of melanoma progression. Cancer. 1994 Feb; 73(3):629-36. doi: 10.1002/1097-0142(19940201)73:3<629::aid-cncr2820730321>3.0.co;2-w. [PMID: 8299084]
  • S Kamei, T Morishima, T Mizutani, T Takasu, T Ochiai, M Kamei, N Nemoto, T Nakayama. Measurement and cytologic demonstration of 5-S-cysteinyldopa for the clinical diagnosis of primary leptomeningeal melanoma. Neurology. 1994 Jan; 44(1):175-6. doi: 10.1212/wnl.44.1.175. [PMID: 8290060]
  • T Horikoshi, S Ito. Serum 5-S-cysteinyldopa (5-S-CD) as a marker of melanoma progression. The Journal of dermatology. 1992 Nov; 19(11):809-13. doi: 10.1111/j.1346-8138.1992.tb03787.x. [PMID: 1293168]
  • H Hara, K Chino, T Kawanami, T Sameshima, T Morishima. 5-S-cysteinyldopa in urine and tumors. The Journal of dermatology. 1992 Nov; 19(11):806-8. doi: 10.1111/j.1346-8138.1992.tb03786.x. [PMID: 1293167]
  • K Yamada, N Walsh, H Hara, K Jimbow, H Chen, S Ito. Measurement of eumelanin precursor metabolites in the urine as a new marker for melanoma metastases. Archives of dermatology. 1992 Apr; 128(4):491-4. doi: . [PMID: 1580656]
  • M Takehara, H Mizuuchi, E Ito, O Hayakawa, S Takashima, H Nei, R Kudo, T Horikoshi, S Ito. [Significance of 5-S-cysteinyldopa on primary malignant melanoma of the female genital organs]. Nihon Sanka Fujinka Gakkai zasshi. 1992 Mar; 44(3):369-72. doi: NULL. [PMID: 1607763]
  • B Kågedal, L Lenner, K Arstrand, C Hansson. The stability of 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid in human urine. Pigment cell research. 1992; Suppl 2(?):304-7. doi: 10.1111/j.1600-0749.1990.tb00390.x. [PMID: 1409435]
  • K Wakamatsu, S Ito, T Horikoshi. Normal values of urinary excretion and serum concentration of 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid, biochemical markers of melanoma progression. Melanoma research. 1991 Jun; 1(2):141-7. doi: 10.1097/00008390-199106000-00009. [PMID: 1823626]
  • L Blomquist, N Dizdar, M Karlsson, B Kågedal, H Ossowicki, A Pettersson, S Smeds. Microdialysis of 5-S-cysteinyldopa from interstitial fluid in cutaneous human melanoma transplanted to athymic mice. Melanoma research. 1991 Apr; 1(1):23-32. doi: 10.1097/00008390-199104000-00004. [PMID: 1822767]
  • U Stierner. Melanocytes, moles and melanoma--a study on UV effects. Acta dermato-venereologica. Supplementum. 1991; 168(?):1-31. doi: NULL. [PMID: 1814138]
  • K M Jin, T Nogita, H Toyoda, M Kawashima, A Hidano. Pedunculated pigmented eccrine poroma of the scalp with increased urinary excretion of 5-S-cysteinyldopa. The Journal of dermatology. 1990 Sep; 17(9):555-8. doi: 10.1111/j.1346-8138.1990.tb01694.x. [PMID: 2177483]
  • N Saito, T Morishima. [Eumelanin and pheomelanin contents in hairs of healthy Japanese and patients with oculocutaneous albinism, and 5-S-cysteinyldopa and 5-hydroxy-6-methoxyindole-2-carboxylic acid levels in urine of oculocutaneous albinism]. Nihon Hifuka Gakkai zasshi. The Japanese journal of dermatology. 1990 Jul; 100(8):853-61. doi: NULL. [PMID: 2122048]
  • Kh Kurbanov, N A Spiridonova. [Tyrosine and methionine metabolism in various states of melaninogenesis]. Biokhimiia (Moscow, Russia). 1990 Jan; 55(1):165-72. doi: . [PMID: 1971518]
  • K Wakamatsu, S Ito, K Fujita. Production, circulation, and excretion of melanin-related metabolites in B16 melanoma-bearing mice. Acta dermato-venereologica. 1990; 70(5):367-72. doi: 102340/0001555570367372. [PMID: 1980967]
  • R Carstam, C Brinck, B Fornstedt, H Rorsman, E Rosengren. 5-S-cysteinyldopac in human urine. Acta dermato-venereologica. 1990; 70(5):373-7. doi: 102340/0001555570373377. [PMID: 1980968]
  • B Kågedal, M Källberg, K Arstrand, C Hansson. Automated high-performance liquid chromatographic determination of 5-S-cysteinyl-3,4-dihydroxyphenylalanine in urine. Journal of chromatography. 1989 Jul; 473(2):359-70. doi: 10.1016/s0021-9673(00)91320-7. [PMID: 2504759]
  • R E Scott, D M Wilson. Role of the clinical laboratory in the diagnosis and management of malignant melanoma. Mayo Clinic proceedings. 1989 Jul; 64(7):837-45. doi: 10.1016/s0025-6196(12)61757-1. [PMID: 2671522]
  • S Ito, K Wakamatsu, S Inoue, K Fujita. Correlation between urinary melanin-related metabolites and tumour weight in melanoma-bearing mice. Acta dermato-venereologica. 1989; 69(5):380-4. doi: . [PMID: 2572100]
  • U Stierner, I Rosdahl, A Augustsson, B Kågedal. Urinary excretion of 5-S-cysteinyldopa in relation to skin type, UVB-induced erythema, and melanocyte proliferation in human skin. The Journal of investigative dermatology. 1988 Nov; 91(5):506-10. doi: 10.1111/1523-1747.ep12476731. [PMID: 3139773]
  • T H Huang, J Wall, P Kabra. Improved solid-phase extraction and liquid chromatography with electrochemical detection of urinary catecholamines and 5-S-L-cysteinyl-L-dopa. Journal of chromatography. 1988 Oct; 452(?):409-18. doi: 10.1016/s0021-9673(01)81464-3. [PMID: 3149647]
  • U Stierner, A Augustsson, I Rosdahl, B Kågedal, M Suurküla. UVB-induced melanocyte proliferation and 5-S-cysteinyldopa excretion in dysplastic nevus syndrome. Photo-dermatology. 1988 Oct; 5(5):218-23. doi: NULL. [PMID: 3146749]
  • L L Peterson, W R Woodward, W S Fletcher, M Palmquist, M A Tucker, A Ilias. Plasma 5-S-cysteinyldopa differentiates patients with primary and metastatic melanoma from patients with dysplastic nevus syndrome and normal subjects. Journal of the American Academy of Dermatology. 1988 Sep; 19(3):509-15. doi: 10.1016/s0190-9622(88)70206-6. [PMID: 3139723]
  • J E Nimmo, D J Gawkrodger, C S O'Docherty, S M Going, I W Percy-Robb, J A Hunter. Plasma 5-S-cysteinyldopa as an index of melanogenesis. The British journal of dermatology. 1988 Apr; 118(4):487-95. doi: 10.1111/j.1365-2133.1988.tb02457.x. [PMID: 3132198]
  • H Rorsman, E Tegner. Biochemical observations in UV-induced pigmentation. Photo-dermatology. 1988 Feb; 5(1):30-8. doi: . [PMID: 3281148]
  • F Hu, W R Woodward, L L Peterson. Plasma 5-S-cysteinyldopa correlates with tumor size in melanoma-bearing mice. The Journal of investigative dermatology. 1988 Feb; 90(2):149-51. doi: 10.1111/1523-1747.ep12462118. [PMID: 3123557]
  • C Hansson. Some indolic compounds as markers of the melanocyte activity. Acta dermato-venereologica. Supplementum. 1988; 138(?):1-60. doi: . [PMID: 3176811]
  • K Wakamatsu, S Ito, K Fujita. Melanin-related metabolites in urine of B16 melanoma-bearing mice. Acta dermato-venereologica. 1988; 68(5):385-9. doi: NULL. [PMID: 2461020]
  • C Hansson, B Kågedal, M Källberg. Determination of 5-S-cysteinyldopa in human urine by direct injection in coupled-column high-performance liquid chromatography. Journal of chromatography. 1987 Sep; 420(1):146-51. doi: 10.1016/0378-4347(87)80165-2. [PMID: 3117824]
  • B Kågedal, A L Gawelin, A Pettersson. Synthesis of 5-S-L-cysteinyl-glycine-L-dopa, a natural substrate for serum and melanocyte dipeptidase. Analytical biochemistry. 1987 Aug; 165(1):167-74. doi: 10.1016/0003-2697(87)90216-8. [PMID: 3120620]
  • J Tardy, J P Barrois, A Bendelac, F Leonard, R Triller, J C Jardillier, B Kalis. Urinary excretion of 5-S-cysteinyldopa is enhanced by PUVA and is independent of skin type. Photo-dermatology. 1987 Aug; 4(4):205-8. doi: NULL. [PMID: 3124084]
  • S Ito, T Kato, K Fujita. Seasonal variation in urinary excretion of 5-S-cysteinyldopa in healthy Japanese. Acta dermato-venereologica. 1987; 67(2):163-5. doi: NULL. [PMID: 2438883]
  • C Beyer, H Fiedler, W Wohlrab, K D Wozniak. [Comparative studies between excretion of 5-S-cysteinyldopa and indole melanogens in urine]. Dermatologische Monatschrift. 1986; 172(9):541-4. doi: NULL. [PMID: 3098590]
  • H Rorsman, P Agrup, B Carlén, C Hansson, N Jonsson, E Rosengren, E Tegner. Trichochromuria in melanosis of melanoma. Acta dermato-venereologica. 1986; 66(6):468-73. doi: NULL. [PMID: 2433864]
  • R A King, R A Lewis, D Townsend, A Zelickson, D P Olds, J Brumbaugh. Brown oculocutaneous albinism. Clinical, ophthalmological, and biochemical characterization. Ophthalmology. 1985 Nov; 92(11):1496-505. doi: 10.1016/s0161-6420(85)33832-0. [PMID: 3935994]
  • C Hansson, L E Wirestrand, A Aronsson, H Rorsman, E Rosengren. Urinary excretion of 6-hydroxy-5-methoxyindole-2-carboxylic acid and 5-S-cysteinyldopa during PUVA treatment. Photo-dermatology. 1985 Apr; 2(2):52-7. doi: NULL. [PMID: 3929237]
  • R Carstam, C Hansson, G Krook, H Rorsman, E Rosengren, L E Wirestrand. Oxidation of dopa in human albinism. Acta dermato-venereologica. 1985; 65(5):435-7. doi: . [PMID: 2416170]
  • J E Nimmo, J A Hunter, I W Percy-Robb, B Jay, C I Phillips, W O Taylor. Plasma 5-S-cysteinyldopa concentrations in oculocutaneous albinism. Acta dermato-venereologica. 1985; 65(2):169-71. doi: NULL. [PMID: 2408424]
  • M C Ekelund, R Carstam, C Hansson, H Rorsman, E Rosengren. Urinary excretion of 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid: differences between pigmented and albino mice. Acta dermato-venereologica. 1985; 65(5):437-9. doi: NULL. [PMID: 2416171]
  • L E Wirestrand, C Hansson, E Rosengren, H Rorsman. Melanocyte metabolites in the urine of people of different skin colour. Acta dermato-venereologica. 1985; 65(4):345-8. doi: NULL. [PMID: 2413694]
  • R Carstam, C Hansson, H Rorsman, E Rosengren, N O Sjöberg, L E Wirestrand. Urinary excretion of melanocytic metabolites in fertile women. Acta dermato-venereologica. 1985; 65(6):543-5. doi: NULL. [PMID: 2420122]
  • S Ito, T Kato, K Maruta, K Fujita, T Kurahashi. Determination of DOPA, dopamine, and 5-S-cysteinyl-DOPA in plasma, urine, and tissue samples by high-performance liquid chromatography with electrochemical detection. Journal of chromatography. 1984 Nov; 311(1):154-9. doi: 10.1016/s0378-4347(00)84702-7. [PMID: 6440898]
  • S Ito, T Kato, K Shinpo, K Fujita. Oxidation of tyrosine residues in proteins by tyrosinase. Formation of protein-bonded 3,4-dihydroxyphenylalanine and 5-S-cysteinyl-3,4-dihydroxyphenylalanine. The Biochemical journal. 1984 Sep; 222(2):407-11. doi: 10.1042/bj2220407. [PMID: 6433900]
  • T Inoi, M Mojamdar, M Ichihashi, Y Mishima. [Therapeutic evaluation of human malignant melanoma by urinary 5-S-cysteinyldopa dynamics: chemotherapy and surgery]. Nihon Hifuka Gakkai zasshi. The Japanese journal of dermatology. 1984 Jan; 94(1):39-43. doi: NULL. [PMID: 6433083]
  • B Kågedal, A Pettersson. Liquid-chromatographic determination of 5-S-L-cysteinyl-L-dopa with electrochemical detection in urine prepurified with a phenylboronate affinity gel. Clinical chemistry. 1983 Dec; 29(12):2031-4. doi: 10.1093/clinchem/29.12.2031. [PMID: 6416708]
  • S Hanawa. [Excretion of 5-S-cysteinyldopa in the urine of Japanese patients with malignant melanoma--a helpful biochemical marker for assessing the progression of disease]. Nihon Hifuka Gakkai zasshi. The Japanese journal of dermatology. 1983 Mar; 93(4):433-42. doi: NULL. [PMID: 6411952]